The company’s revolutionary Tesseract iC™ brings in a new class of diagnostics, using retinal imaging to see chemistry and diagnose diseases GUILFORD, Conn., April 20, 2021-- Tesseract HealthTM Inc. has raised $80 million in an oversubscribed Series B financing round -- with support from investors including Foresite Capital, Glenview Capital, and Opaleye -- to advance the development of the company’s groundbreaking Tesseract iC™ eye-imaging diagnostic technology platform. The funds will be used to conduct research to advance the Tesseract iC platform, accelerate the company’s push to obtain US and international regulatory clearances, and ramp up manufacturing.